Short Interest in Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) Drops By 38.4%

Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) saw a large decrease in short interest in July. As of July 15th, there was short interest totaling 51,582 shares, a decrease of 38.4% from the June 30th total of 83,765 shares. Based on an average daily volume of 36,650 shares, the short-interest ratio is currently 1.4 days. Approximately 5.2% of the company’s stock are short sold.

Institutional Investors Weigh In On Virtus LifeSci Biotech Clinical Trials ETF

An institutional investor recently bought a new position in Virtus LifeSci Biotech Clinical Trials ETF stock. Worth Asset Management LLC bought a new position in shares of Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,093 shares of the company’s stock, valued at approximately $216,000. Worth Asset Management LLC owned 0.41% of Virtus LifeSci Biotech Clinical Trials ETF as of its most recent filing with the Securities and Exchange Commission (SEC).

Virtus LifeSci Biotech Clinical Trials ETF Stock Performance

Shares of BBC stock traded down $1.53 during trading hours on Friday, hitting $48.74. 14,729 shares of the company were exchanged, compared to its average volume of 24,062. Virtus LifeSci Biotech Clinical Trials ETF has a one year low of $20.87 and a one year high of $54.95. The business’s 50-day simple moving average is $47.81 and its two-hundred day simple moving average is $44.30.

About Virtus LifeSci Biotech Clinical Trials ETF

The Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is managed by Virtus.